• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Gastroenterol Hepatol . Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospe

tetano

Editor, Senior Moderator
Eur J Gastroenterol Hepatol


. 2020 Aug 28.
doi: 10.1097/MEG.0000000000001902. Online ahead of print.
Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study


Mahmud Mahamid[SUP] 1 2 [/SUP], Wiliam Nseir[SUP] 3 [/SUP], Tawfik Khoury[SUP] 4 5 6 [/SUP], Baker Mahamid[SUP] 6 [/SUP], Adi Nubania[SUP] 1 2 [/SUP], Kamal Sub-Laban[SUP] 1 2 [/SUP], Joel Schifter[SUP] 1 2 [/SUP], Amir Mari[SUP] 5 6 [/SUP], Wisam Sbeit[SUP] 4 5 [/SUP], Eran Goldin[SUP] 1 2 [/SUP]



Affiliations

Abstract

Aim: Coronavirus disease 2019 (COVID-19) is a recently encountered disease that was declared a pandemic by WHO in 2020. Obesity and other components of the metabolic syndrome may aggravate the severity of COVID-19. Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome. The aim of this study was to investigate a possible association between MAFLD and COVID-19 severity.
Methods: We performed a retrospective, case-control study, enrolling 71 consecutive COVID-19 patients who were divided into two groups according to the presence or absence of fatty liver by computed tomography scan. All medical records of eligible patients were reviewed including demographic, clinical, laboratory parameters and data regarding the presence of NAFLD and COVID-19 severity.
Results: NAFLD was identified in 22/71 (31%) of the study group. Out of 71, thirteen suffered from severe COVID-19. NAFLD patients had more severe COVID-19 compared with non-NAFLD subjects, 8/22 (36.3%) vs. 5/49(10.2%), (P < 0.005), respectively. Multiple logistic regression analysis showed that NAFLD subjects were more likely to have severe COVID-19 disease (odds ratio 3.57, 95% confidence interval: 1.22, 14.48, P = 0.0031).
Conclusion: NAFLD represents a high risk for severe COVID-19 irrespective to gender, and independent of metabolic syndrome specifically in male gender. Moreover, obesity, hypertension and metabolic syndrome were also significantly associated with severe COVID-19.
 
Back
Top Bottom